Jim Cramer Shed Light on These 14 Stocks
“Right now, it is a wild chase, a mad dash so to speak, to make money wherever it can be found, IPOs, mergers and acquisitions, giant upside surprises.
Arcus Biosciences Inc. (RCUS)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Point72 Asset Management Steve Cohen | 5,966,664 | $48,568,642 | +109% | 0.1% |
| 2. | Woodline Partners Michael Rockefeller And Karl Kroeker | 4,000,029 | $32,560,236 | -22% | 0.17% |
| 3. | Suvretta Capital Management Aaron Cowen | 3,688,858 | $30,027,304 | +45% | 0.91% |
| 4. | 1,707,500 | $13,899,050 | 0.02% | ||
| 5. | Siren L.L.C. Raymond Debbane | 1,612,077 | $13,122,307 | 0.68% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.06 | 20,000 | $201,200.00 | 28,400 | 2025-02-27 | Filing | |
| $10.18 | 19,800 | $201,465.00 | 2,554,160 | 2025-02-27 | Filing | |
| $11.00 | 1,363,636 | $14,999,996.00 | 31,424,760 | 2025-02-18 | Filing | |
| $21.00 | 15,238,095 | $319,999,995.00 | 30,061,124 | 2024-01-29 | Filing | |
| $19.26 | 1,010,000 | $19,452,600.00 | 14,823,029 | 2023-06-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.05 | 37,792 | $568,610.87 | 214,232 | 2025-10-08 | Filing | |
| $14.54 | 12,500 | $181,801.25 | 214,232 | 2025-10-06 | Filing | |
| $13.00 | 2,831 | $36,803.00 | 27,363 | 2025-09-29 | Filing | |
| $11.88 | 1,579 | $18,758.05 | 30,194 | 2025-09-05 | Filing | |
| $15.00 | 3,594 | $53,910.00 | 60,138 | 2024-12-31 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 30,562 | $415,643 | 0% | |
| 2. | 21,533 | $292,849 | 0% | |
| 3. | 2,748 | $37,373 | 0% | |
| 4. | 1,700 | $23,120 | 0% | |
| 5. | 180 | $2,448 | 0% |
News See All
Arcus Biosciences' Pancreatic Cancer Drug Quemliclustat Receives Orphan Drug Designation from FDA
Arcus Biosciences Inc. (NYSE:RCUS) is one of the biotech stocks to buy according to Wall Street analysts.
10 Biotech Stocks to Buy According to Wall Street Analysts
On July 8, Jared Holz, Mizuho, joined 'Closing Bell Overtime' on CNBC to discuss if the biotech sector is ready for a breakout.
12 Small Cap Stocks with High Upside Potential
The trade war saga between the U.S. and China appears to be nearing a conclusion, as China’s Ministry of Commerce shared details on the trade deal on June 27.
Arcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer Treatment
Arcus Biosciences, Inc. (NYSE:RCUS) is one of the 12 Small Cap Stocks with High Upside Potential.
Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2025 Earnings Call Transcript
Operator: Hello, everyone. And welcome to Arcus Biosciences First Quarter 2025 Earnings and Financial Results Call. My name is Lydia, and I'll be your operator today.
Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, thank you for attending today's Arcus Biosciences Third Quarter 2024 Earnings Call. My name is Tamiya and I will be your moderator for today's call.
Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2024 Earnings Call Transcript
Arcus Biosciences, Inc. beats earnings expectations. Reported EPS is $-0.05, expectations were $-0.97. Arcus Biosciences, Inc.
Arcus Biosciences, Inc. (NYSE:RCUS) Q4 2023 Earnings Call Transcript
Operator: Hello and welcome to the Arcus Biosciences Full Year/Q4 2023 Earnings Call. My name is Elliot, and I’ll be coordinating your call today. [Operator Instructions].
Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript
Operator: Thank you and welcome to the call. Following prepared remarks from the Company, we will open the call for questions.